Welcome to JADPRO Live Spotlights!
Get the advanced practice perspective on the latest information presented at JADPRO Live and more. Our AP experts share what they learned, how it will impact their practice, and what they look forward to sharing with their colleagues.
New Drug Updates in Hematologic Malignancies & Establishing a Survivorship Program in a Malignant Hematology and Cellular Therapy Practice
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, of Minnesota Oncology and the Mayo Clinic College of Medicine, discusses notable FDA approvals and expansions in the BTKi space and antibody drug conjugates, aimed at B-cell cancers, including DLBCL, and the BRUIN study, which looked at the promising use of pirtobrutinib in patients with CLL and SLL. He also reviewed some of the challenges of setting up a survivorship program for patients with hematologic malignancies. He describes the crucial role advanced practice providers can play in determining the optimal timing for survivorship care plans and referral to survivorship care, as well as developing long-term follow-up strategies (Abstract JL1130C).Watch Spotlight
Rose DiMarco, PharmD, BCPS, BCOP, of the Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, discusses a presentation that reviewed practice guideline updates for patients with metastatic HER2-overexpressing breast cancer, the increased clinical relevance of the new “HER2-low” category of HER2 expression, and best practices when monitoring and managing adverse events associated with novel HER2-targeted agents for advanced disease.Watch Spotlight
Sarah E. Sagorsky, MPAS, PA-C, of the Sidney Kimmel Cancer Center on the Bayview campus, discusses a presentation that reviewed new molecular-targeted treatment options for patients with metastatic non-small cell lung cancer, related updates to clinical practice guidelines, the implications of biomarker testing, and evidence-based best practices for monitoring and managing adverse events associated with these therapies.Watch Spotlight
Amy Pierre, MSN, RN, ANP-BC, of Memorial Sloan Kettering Cancer Center and Flatiron Health, discusses a presentation about managing patients with newly diagnosed multiple myeloma; what to consider in early relapse disease, including the use of triplets in patients with one-to-three prior lines of therapy; and sequencing treatments (bispecifics and CAR-T therapy) in advanced disease.Watch Spotlight
New Drug Updates in Hematologic Malignancies, Development of an Advanced Practice Provider-Led Virtual Anemia Consult Clinic, Indirect Treatment Comparison of Momelotinib vs Pacritinib Safety and Anemia Outcomes in Patients With Myelofibrosis
Susan Woodward, MSN, APRN, AOCNP®, of Moffitt Cancer Center, discusses bispecific antibodies that were approved in the past year as well as other drugs for FL, MM, and MF, and the new set of toxicities these agents bring with them. She also reviewed a poster that showed a model developed by APs to expedite the evaluation and management of anemia in patients with cancer, improving health-care access for patients coping with anemia (Abstract JL1112C). Another poster she reviewed compared safety outcomes between momelotinib and fedratinib separately in JAK inhibitor–experienced and JAK inhibitor–naïve patients with myelofibrosis (Abstract JL1109EH).Watch Spotlight
New Drug Updates in Hematologic Malignancies & Patient Perspectives on Returning to Cancer Care in a PostCOVID Environment
Ann McNeill, RN, NP, MSN, APN, of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the advancements in ADC, BTKi, and bispecific antibodies drugs for R/R MM, lymphoma and AML. She also reviews the challenges faced by patients with cancer during the COVID-19 pandemic. Insights from these patients can help advanced practitioners better understand the hurdles to accessing cancer care in the post-pandemic healthcare environment in which inequalities and vulnerabilities remain (Abstract JL1112P).Watch Spotlight